Flagship · Bulletin

Macro rationale

Macro digest holds neutral: regime_signal=neutral, VIX 16.9, HY OAS 2.67, NFCI -0.516 — a confirmed complacency gap against +57K NFP and live Hormuz/Houthi escalation. Extension (QQQ +13.48%) and concentration (AI 42% NAV) escalators are active, which is why the brief argues for elevated cash. This is an event-driven patch triggered by a mechanical §2/§3 biology pillar-floor breach (scoped [LLY,MU], entry-evaluation opens [VRTX,ARGX,NVO,RGEN,ILMN,SDGR]), not a regime signal. No policy shock hit any pillar this week; compute score-drift remains the Warsh-Fed discount-rate compression story (MU's ~$100B SCA book keeps confirming AI-capex demand is structurally intact), not a demand break. Regime stays neutral; the only action is the mandatory floor cure.

Thesis

Scope-locked event-driven patch. The binding action is the §2/§3 biology pillar-floor cure: biology is a fragile single-name pillar (LLY only, 10% entry-weight, below floor on the over-bought normalized basis). Rather than pile more into LLY (already at 10%, worsening single-name concentration), I cure the floor by re-establishing VRTX — the highest-conviction durable biology compounder in scope (score 76: Trikafta CF monopoly cash engine, self-funded, high margins, Casgevy + Journavx optionality). VRTX was closed 3 days ago only as a sub-1% dust artifact of iterative trimming, not a thesis break — re-establishing it at a real 3% weight corrects that churn error, gives biology a durable second leg (LLY 10% + VRTX 3% = 13%, comfortably over floor), and moves the book 16→17 toward the 18-20 band. Funded entirely from cash (8.18%→5.18%, inside the NEUTRAL base band). Every other in-scope compute name and all out-of-scope names hold verbatim at delta 0 per the scope lock and my unchanged read — compute drift is discount-rate, not demand. No trims, no other opens. Book remains at 17 vs the band; the residual gap closes at the next full deep run.

Reflection

Mandatory §2/§3 biology pillar-floor cure — establishing a durable second biology leg (VRTX) beyond fragile single-name LLY. No flow shift elsewhere; compute/energy/defense held verbatim.

The VRTX dust-close 3 days ago was itself the churn error this strategy warns against — iterative trimming took a durable CF-monopoly compounder to <1% and auto-closed it, not a thesis break. This floor-cure run is the right moment to re-establish it at a real 3% weight, which also finally nudges the book 16→17 toward the band. The tension I hold: re-entry 3d after close is a fast_reversal flag, but the exit was mechanical dust, not conviction, and VRTX is the highest-score (76) durable biology name in scope and the exact second-leg I named last run. Cash goes 8.18→5.18% (band floor) to fund i

Positions (17)

• MUMicron Technologycompute

  hold3.54%79
  flow acceleratingconf

  Funder

  US HBM3E/HBM4 supplier in a capacity-disciplined memory cycle; blowout FQ3 (+17% rev/+22% op-income), 16 Strategic Customer Agreements covering ~20% DRAM / ~1/3 NAND through 2030 (~$100B contracted). Rides the ~$725B 2026 hyperscaler capex line + $3B US supply-chain investment.

  Unwind

  DRAM/NAND spot-price collapse or HBM oversupply breaking the shortage thesis; hyperscaler capex cut; SCA book erosion.

  Catalyst

  Next FQ earnings + HBM4 qualification progress.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold7.76%83
  flow steadyconf

  Funder

  Leading-edge foundry monopoly (<3nm), >50% gross margin, prodigious FCF, disciplined capex — routes the world's AI silicon. Goldman's $920B-$1.4T 2027 AI-capex forecast names TSMC explicitly; CHIPS $6.6B Arizona disbursement; Meta AI-chip sourcing agreement.

  Unwind

  Competitor 3nm yield convergence; gross margin compression below 50%; a genuine AI-capex cut (not KOSPI-margin liquidation noise).

  Catalyst

  Q2 earnings / capex guide.

• NVDANVIDIAcompute

  hold2.89%72
  flow steadyconf

  Funder

  CUDA/accelerator software moat, ~75% gross margin, fortress balance sheet. ~$725B 2026 hyperscaler capex anchored on Blackwell/Rubin (MSFT $190B, AMZN $200B, GOOGL $180-190B, META $125-145B); Stargate $500B JV.

  Unwind

  Hyperscaler ASIC displacement of merchant GPU; gross margin break below ~70%; a hyperscaler capex guide-down. Score 72, held above hard-exit; no add until >80.

  Catalyst

  Hyperscaler capex prints (MSFT/GOOGL July guidance).

• ASMLASML Holdingcompute

  hold3.68%64
  flow steadyconf

  Funder

  EUV lithography monopoly — the single most irreplaceable tool in advanced semis, ~50% gross margin, multi-year backlog, no commercial-scale alternative. Norway GPFG holds; Coatue/Third Point added Q1; SK Hynix $28B listing + MS/Bernstein PT raises confirm EUV demand.

  Unwind

  Book-to-bill breaks below threshold at Q2 results; a commercial EUV alternative; large order cancellations. Score 64 — trim discipline engages only below 60.

  Catalyst

  July 15 Q2 bookings / book-to-bill.

• AVGOBroadcomcompute

  hold2.25%62
  flow steadyconf

  Funder

  Custom-silicon ASIC leader (~70% share) + VMware software, huge FCF, $7B+ buyback, serial dividend grower. GOOG TPU multi-gen, META MTIA, Anthropic 3.5GW ASIC contracts; Apple 10-yr partnership; OpenAI custom-chip work.

  Unwind

  ASIC share loss; AI-segment bookings disappoint next print; FCF/buyback break. Score 62, 2pts above broken threshold — hard review if <60.

  Catalyst

  Next earnings custom-chip revenue trajectory vs $25B run-rate.

• ANETArista Networkscompute

  hold1.93%67
  flow steadyconf

  Funder

  Durable hyperscaler-networking franchise, share-gainer since 2004, ~65% gross margin, net cash, single-image EOS software moat, Ullal-led capital discipline. Microsoft & Meta named largest customers funding 35% YoY revenue growth; Morgan Stanley PT $190.

  Unwind

  NVDA Spectrum-X displacing Arista in a major footprint; forward P/E >45x with growth decel; hyperscaler in-house switching pivot.

  Catalyst

  Next earnings; hyperscaler switching capex.

• FNcompute

  hold1.37%63
  flow steadyconf

  Funder

  Optical transceiver/packaging manufacturer interconnecting hyperscaler AI clusters; capital-light, debt-free, extracts hyperscaler capex without silicon R&D risk. AWS dominant customer drove ~36% YoY growth; record $1.2B quarterly revenue; 800G/1.6T demand.

  Unwind

  P/E >35x during decelerating growth; Datacom sequential-growth break; gross-margin compression. Second-hyperscaler 800G design-win still unverified.

  Catalyst

  Next earnings Datacom sequential growth + 800G design-win.

• CCJCamecoenergy

  hold8.13%65
  flow steadyconf

  Funder

  Tail-risk hedge slot: tier-1 Saskatchewan uranium franchise + Westinghouse 49% JV with Brookfield. DOE $17.5B AP1000 loan commitment, Kazatomprom 8Mlb output cut sustaining a structural deficit, contract book $60+/lb vs ~$93 term market, AI-driven nuclear demand.

  Unwind

  Uranium spot/term price collapse; contract-book erosion; DOE loan program withdrawal. Score drift (65) alone is not a trim trigger — thematic tailwind intact.

  Catalyst

  Term-price prints; reactor-restart/PPA announcements.

• GEVGE Vernovaenergy

  hold7.51%63
  flow steadyconf

  Funder

  Gas-turbine + grid franchise with pricing power — ~$163B backlog (to ~$200B by 2027), 100GW turbine backlog, 10-20% price realization. Norway GPFG added post-spin; Oracle $90-95B FY27 + Alphabet $80B capex pull-through; Chevron 20-yr agreement.

  Unwind

  Backlog cancellation or wind-loss deterioration; EV/EBITDA breaching ~25x exit ceiling; a hyperscaler power-capex cut.

  Catalyst

  Q2 orders / backlog update.

• SCCOSouthern Copperenergy

  hold7.53%63
  flow steadyconf

  Funder

  Tail-risk hedge slot: lowest-cost copper producer, vast reserves, fat margins, large dividend. Copper supply deficit ~320k tonnes 2026, record Q1 NI $1.58B, AI/data-center ~30% of new copper demand by 2030 (BloombergNEF); Mexican-gov (Grupo Mexico) backstop owner.

  Unwind

  Copper price collapse below entry thesis; Peru/Mexico permitting shock; AI/grid demand thesis break.

  Catalyst

  Copper price direction; Q2 earnings.

• MPMP Materialsenergy

  hold4.48%
  flow softeningconf

  Funder

  Only scaled US rare-earth + magnet producer; DoD $400M Series A preferred + $150M loan + 10-yr $110/kg NdPr price floor + 10-yr magnet offtake for the 10X facility — a government-backstopped moat vs China's ~98% magnet control.

  Unwind

  FCF stays negative through the magnet ramp; China blacklist chokes processing-tech access materially; 10X facility construction slips; DoD backstop withdrawn.

  Catalyst

  10X facility magnet-ramp / FCF inflection; China MOFCOM No.23 mitigation.

• NEMNewmont Corporationenergy

  hold5.43%89
  flow softeningconf

  Funder

  Tail-risk equity hedge (§5.3/10.2): largest gold producer, tier-1 long-life assets, strong post-Newcrest FCF and dividend, improving cost discipline. Red Chris JV secured $500M Canadian-government backing; central-bank gold accumulation floor.

  Unwind

  Gold sustained bear market driven by rising real yields (Fed-credibility repricing, not stagflation) evaporating the tail bid; cost inflation; FCF break.

  Catalyst

  Gold price stabilization; Q2 cost/production update.

• KTOSKratos Defensedefense

  hold9.25%
  flow steadyconf

  Funder

  Tactical drones (XQ-58 Valkyrie), hypersonics, turbine engines — DAWG-adjacent defense-tech. DoD MACH-TB 2.0 $1.45B IDIQ, Project Helios $68.3M, USMC Valkyrie mods; FY27 DAWG ~$54.6B line; UK £5B drone program; ARK accumulation.

  Unwind

  FY27 DAWG appropriations cut; revenue-inflection/margin-firming fails to confirm; quarterly contract flow stalls. Held at delta 0 per scope lock.

  Catalyst

  Next quarterly contract flow / revenue-inflection print.

• HEIHEICOdefense

  hold9.26%68
  flow steadyconf

  Funder

  Defense/aero aftermarket compounder — Mendelson family owners since 1957, 20%+ FCF CAGR, disciplined serial acquirer ($1B+/yr). Record Q2 (net income +49% YoY, sales $1.375B +25%, ETG op-income +56%); NDAA mandatory funding + commercial-aero MRO; Buffett holding.

  Unwind

  Forward P/E >50x without accelerating growth; organic growth below the ~6% floor; a value-destroying acquisition or capital-allocation break.

  Catalyst

  Next quarterly organic-growth trajectory vs ~6% floor.

• PSNdefense

  hold2.91%50
  flow softeningconf

  Funder

  C5ISR/cyber government-services prime, sticky multi-year IDIQ backlog: MDA SHIELD $151B-ceiling IDIQ, DTRA cyber $137M, USAF MATOC $15B, Navy WEXMAC $10B, plus $1.1-1.4B Blatnik Bridge win and Qatar Lusail contract.

  Unwind

  Score already 50 (below 60 floor); SHIELD task-order conversion continues to fail; book-to-bill deteriorates further. Weakening — flagged for review but held at delta 0 per scope lock.

  Catalyst

  MDA SHIELD task-order conversion; 2026 guidance $6.5-6.8B execution.

• LLYEli Lillybiology

  hold7.00%70
  flow steadyconf

  Funder

  Premier pharma compounder — Mounjaro/Zepbound GLP-1 franchise (~60% US GLP-1 share, $12B+ quarterly sales) + oral orforglipron (Foundayo) FDA-approved Apr 2026 + retatrutide Ph3 (~70lb loss); 82.9% margin, fcf+, $27B manufacturing expansion; Norway GPFG holder.

  Unwind

  10pt US GLP-1 share loss to NVO; retatrutide Ph3 failure; margin/FCF deterioration; a CMS Part-D/IRA pricing shock. Profitable compounder, not rate-vise cash-burn biotech.

  Catalyst

  Retatrutide Ph3 readouts; Foundayo launch trajectory; CMS Part-D updates.

• VRTXVertex Pharmaceuticalsbiology

  hold3.00%76
  flow acceleratingconf

  Funder

  Durable biology compounder: cystic-fibrosis monopoly (Trikafta) cash engine, self-funded, high margins, fortress balance sheet — a genuine 20-30yr franchise. Tailwind: Casgevy commercializing across 12+ jurisdictions with the Medicare Cell & Gene Therapy Access Model (a named federal reimbursement flow); Journavx (suzetrigine) non-opioid pain launch; Crinetics deal adds endocrine optionality; Norw

  Unwind

  Trikafta patent/competitive erosion breaking the CF cash engine; Casgevy reimbursement (Medicare Access Model) stalls; margin/FCF deterioration; a value-destroying M&A turn.

  Catalyst

  Casgevy pediatric expansion + Medicare Access Model reimbursement; Journavx launch progression; Q2 earnings.

Warnings

• stale_policy guard: VRTX open → hold (delta zeroed)
• §2 cap re-applied after pillar tilt: MU
• §2 cap re-applied after pillar tilt: NVDA
• §2 cap re-applied after pillar tilt: AVGO
• §2 cap re-applied after pillar tilt: ANET
• §2 cap re-applied after pillar tilt: FN
• §2 cap re-applied after pillar tilt: GEV
• §2 cap re-applied after pillar tilt: MP
• §2 cap re-applied after pillar tilt: NEM
• §2 cap re-applied after pillar tilt: KTOS
• §2 cap re-applied after pillar tilt: HEI
• §2 cap re-applied after pillar tilt: PSN
• §2 cap re-applied after pillar tilt: LLY
• §2 cap re-applied after pillar tilt: VRTX
• position_count: 17 < 18 after mechanical closes (§2 floor) — book under-populated; strategist must open replacements next run
• §6.6 entry floor: VRTX open dragged to 2.11pp by renormalization (model intent 3pp ≥ 3pp) → floored at 3pp, not left a token position
• ledger stale (ledger over-bought (cash -34.52% of NAV)) — rebalance diffed against intent

Conviction-lock actions

1. Turn 1ConvictionGuard (§6.5d)

   —
2. Turn 2ConvictionGuard (§6.5d)

   —

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.